natgillin/translations-raw huggingface dataset:
Crushed prednisolone tablets were compared to prednisolone syrup (with sorbitol), in children with acute asthma, using dyspnoea as clinical end point. 
Zdrobljene tablete prednizolona so primerjali s prednizolonom v obliki sirupa (s sorbitolom) pri otrocih z akutno astmo, pri čemer so za oceno kliničnega končnega učinka uporabili dispnejo.
The active ingredient in Okrido, prednisolone sodium phosphate, is ‘freely soluble in water' (Ph Eur). 
Aktivna učinkovina v zdravilu Okrido, prednizolon natrijev sulfat, je „dobro topna v vodi” (Evropska farmakopeja).
The permeability data is reflective of the available literature, which indicates that prednisolone is rapidly and almost completely absorbed across the upper gastrointestinal tract. 
Podatki o permeabilnosti odražajo razpoložljive podatke iz literature, ki navajajo, da se prednizolon hitro in skoraj v celoti absorbira v vsem zgornjem delu gastrointestinalnega trakta.
Okrido is an oral solution containing 6 mg/ml of the glucocorticoid prednisolone, as prednisolone sodium phosphate (PSP). 
Okrido je peroralna raztopina, ki vsebuje 6 mg/ml glukokortikoida prednizolona v obliki prednizolon natrijevega fosfata (PSP).
The permeability data is reflective of the available literature data, which indicate that prednisolone is rapidly and almost completely absorbed passively from the upper gastrointestinal tract. 
Podatki o permeabilnosti odražajo razpoložljive podatke iz literature, ki navajajo, da se prednizolon hitro in skoraj v celoti pasivno absorbira v zgornjem delu gastrointestinalnega trakta.
4 Chen M. Straughn A, Sadrieh N. et al (2007). 
Pharm. Res. 24, 73-80. 4 Chen M. Straughn A, Sadrieh N. et al (2007).
Solubility and dissolution are not considered to be a limiting factor in terms of in vivo absorption. 
Topnost in raztapljanje se ne štejeta za omejitveni dejavnik v smislu absorpcije in vivo.
Solubility and/or dissolution are therefore not considered to be a limiting factor in terms of in vivo absorption. 
Topnost in/ali raztapljanje se zato ne štejeta za omejitveni dejavnik v smislu absorpcije in vivo.
- Prednisolone (as sodium phosphate) exhibits high permeability as determined by the in vitro Caco-2 cell permeability model, and the permeability of Okrido is unaffected by the excipient sorbitol. 
- prednizolon (kot natrijev fosfat) izkazuje visoko permeabilnost, kot je dokazal in vitro celični model permeabilnosti Caco-2, na permeabilnost zdravila Okrido pa pomožna snov sorbitol ne vpliva;
the CHMP has recommended the granting of the marketing authorisation for which the summary of product characteristics, labelling and package leaflet remain as per the final versions achieved during the Coordination group procedure as mentioned in Annex III of this Opinion. 
• odbor je zato sklenil, da je izvzetje študij biološke enakovrednosti upravičeno in da je razmerje med tveganji in koristmi za zdravilo Okrido za uporabljene indikacije ugodno; je odbor CHMP priporočil odobritev dovoljenja za promet z zdravilom, za katerega povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo ostajajo enaki kot zadnje različice, pripravljene med postopkom skupine za usklajevanje, kot je navedeno v Prilogi III tega mnenja.
Both Okrido and the reference product are dissolved in water before administration and are considered to be oral solutions, which exhibit high solubility across the gastrointestinal physiological pH range. 
Zdravilo Okrido in referenčno zdravilo je treba pred dajanjem raztopiti v vodi in se štejeta za peroralni raztopini, ki izkazujeta veliko topnost v razponu fiziološkega pH prebavil.
- Both Okrido and the reference product are dissolved in water before administration and are considered to be oral solutions, which exhibits high solubility across the gastrointestinal physiological pH range. 
- je zdravilo Okrido in referenčno zdravilo treba pred dajanjem raztopiti v vodi in se štejeta za peroralni raztopini, ki izkazujeta veliko topnost v razponu fiziološkega pH prebavil.
Permeability has been investigated using in vitro Caco-2 monolayer cell model and the results showed that prednisolone exhibits high permeability characteristic of BCS class I substances, and also that the permeability of prednisolone is not significantly affected by the excipient sorbitol in Okrido. 
Permeabilnost so preiskovali z uporabo enoplastnega in vitro celičnega modela Caco-2, rezultati pa so pokazali, da prednizolon izkazuje visoko permeabilnost, značilno za snovi razreda I po biofarmacevtskem sistemu klasifikacije (BCS), in da pomožna snov sorbitol v zdravilu Okrido ne vpliva bistveno na permeabilnost prednizolona.
In summary, the results of the in vitro investigation of the permeability of prednisolone using the Caco-2 cell model showed that prednisolone exhibits high permeability, characteristic of BCS class I substances, and also that the permeability of prednisolone is not affected by the excipient sorbitol in Okrido. 
Rezultati in vitro preiskave permeabilnosti prednizolona z uporabo celičnega modela Caco-2 so pokazali, da prednizolon izkazuje visoko permeabilnost, značilno za snovi razreda I po biofarmacevtskem sistemu klasifikacije (BCS), ter da na permeabilnost prednizolona ne vpliva pomožna snov sorbitol v zdravilu Okrido.
The CMDh therefore referred the matter to the CHMP through an Art 29(4) referral procedure. 
Skupina za usklajevanje za postopek z medsebojnim priznavanjem in decentralizirani postopek za zdravila za uporabo v humani medicini je zato zadevo napotila na odbor CHMP prek napotitvenega postopka po členu
‘Oral solutions 
„Peroralne raztopine
A positive opinion was therefore adopted on 20 January 2005. 
Tako je bilo pozitivno mnenje sprejeto 20. januarja 2005.
The arbitration procedure started on 16 September 2004. 
Postopek obravnave se je začel 16. septembra 2004.
London, 10 May 2005 EMEA/CHMP/94618/2005 
London, 10-05-2005 EMEA/CHMP/94618/2005
The final opinion was converted into a Decision by the European Commission on 10 May 2005. 
Končno mnenje je bilo dne 10-05-2005 spremenjeno v Odločbo Evropske komisije.
During its January 2005 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that a marketing authorisation should be granted. 
Na svojem zasedanju januarja 2005 je CHMP glede na celotne predložene podatke in znanstveno razpravo znotraj Odbora menil, da se dovoljenje za promet z zdravilom lahko podeli.
The application for Mutual Recognition for Rigevidon was submitted to Denmark and the Mutual Recognition Procedure started on 30 April 2004. 
Danska je zatem prejela vlogo za medsebojno priznavanje Rigevidona in 30. aprila 2004 se je začel postopek za medsebojno priznavanje.
Rigevidon is a combined oral contraceptive (COC) containing 150µg levonorgestrel (LNG) and 30µg ethinylestradiol (EE2). 
Rigevidon je kombinirano peroralno kontracepcijsko sredstvo (COC), ki vsebuje 150µg levonorgestrela (LNG) in 30µg etinilestradiola (EE2).
The referral procedure was triggered by the Netherlands, in relation to the acceptance criteria, in bioequivalence studies, of pharmacokinetics parameters, which may need to be tightened, if Rigevidon could be considered as a medicinal product with a narrow therapeutic range. 
Nizozemska je sprožila napotitveni postopek v zvezi z merili za sprejemljivost farmakokinetičnih parameterov v študijah bioekvivalence, ki jih je potrebno strožje opredeliti, da se lahko Rigevidon prizna kot zdravilo z ozkim terapevtskim razponom.
The list of product names concerned is given in the Annex I. The scientific conclusions are provided in the Annex II, together with the Summary of Product Characteristics in the Annex III. 
Seznam zadevnih imen proizvodov je naveden v Prilogi I. Znanstveni zaključki so podani v Prilogi II,
A Marketing Authorisation for Rigevidon was granted to Medimpex France SA by Denmark on 10 
Danska je 10. marca 2003 družbi Medimpex France SA za Rigevidon podelila dovoljenje za promet z zdravilom.
International Non-Proprietary Name (INN): levonorgestrel and ethinylestradiol 
MNENJE V ZVEZI Z NAPOTITVIJO IZ ČLENA 29(2) Rigevidon Mednarodno nelastniško ime (INN): levonorgestrel in etinilestradiol
Outcome of a procedure under Article 13(2) of Regulation (EC) 1234/2008 
Izid postopka v skladu s členom 13(2) Uredbe (ES) 1234/2008
The Committee looked at the study presented by the company to support its application. 
Odbor je pregledal študijo, ki jo je družba predložila v podporo vlogi.
The company that markets these medicines is Mundipharma GmbH. 
Ta zdravila trži farmacevtska družba Mundipharma GmbH.
However, the Member States were unable to reach agreement on whether to accept this new indication and on 2 May 2014, Germany referred the matter to the CHMP for arbitration. 
Vendar države članice niso uspele doseči soglasja glede odobritve te nove indikacije, zato je Nemčija 2. maja 2014 zadevo napotila v arbitražo odboru CHMP.
The European Commission issued an EU-wide legally binding decision to implement this change on 22 December 2014. 
Evropska komisija je 22. decembra 2014 izdala pravno zavezujoči sklep o izvajanju navedene spremembe, ki velja za celotno EU.
On 23 October 2014, the European Medicines Agency completed an arbitration procedure for Oxynal, Targin and associated names. 
Evropska agencija za zdravila je 23. oktobra 2014 končala postopek arbitraže za zdravila Oxynal, Targin in povezana imena.
Restless legs syndrome is a disorder where the patient has uncontrollable urges to move the limbs to stop uncomfortable, painful or odd sensations in the body, usually at night. 
Sindrom nemirnih nog je motnja, pri kateri ima bolnik nenadzorovano potrebo po premikanju udov, s katerim poskuša preprečiti neudobne, boleče ali čudne občutke v telesu, navadno ponoči.
Oxynal, Targin and associated names are marketed in all EU Member States except Croatia, Greece, Lithuania and Malta. 
Zdravila Oxynal, Targin in povezana imena se tržijo v vseh državah članicah EU, razen na Hrvaškem, v Grčiji, Litvi in na Malti.
Regarding the safety, the CHMP concluded that overall the risk of tolerance and misuse is considered low and that the proposed measures to reduce this risk are appropriate. 
Glede varnosti je odbor CHMP menil, da je splošno tveganje za toleranco in zlorabo majhno ter da so predlagani ukrepi za zmanjšanje tega tveganja ustrezni.
Oxynal and Targin have been authorised in the EU under a mutual recognition procedure based on an initial authorisation granted by Germany. 
Zdravili Oxynal in Targin sta v EU odobreni s postopkom medsebojnega priznavanja na podlagi prvotnega dovoljenja, ki ga je odobrila Nemčija.
The company wanted the authorisation for the additional use in restless legs syndrome to be recognised in the following Member States: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Hungary, Ireland, Italy, Latvia, Luxembourg, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the United Kingdom (the ‘concerned Member States'). 
Družba je želela, da se dovoljenje za dodatno uporabo pri sindromu nemirnih nog prizna v naslednjih državah članicah: v Avstriji, Belgiji, Bolgariji, na Cipru, v Češki republiki, na Danskem, v Estoniji, na Finskem, v Franciji, na Madžarskem, Irskem, v Italiji, Latviji, Luksemburgu, na Nizozemskem, Norveškem, Poljskem, Portugalskem, v Romuniji, na Slovaškem, v Sloveniji, Španiji, na Švedskem in v Združenem kraljestvu („zadevne države članice“).
Why was Oxynal and Targin reviewed? 
Zakaj sta bili zdravili Oxynal in Targin pregledani?
Oxynal and Targin are medicines used to treat severe pain that can only be managed with opioids. 
Oxynal in Targin sta zdravili, ki se uporabljata za zdravljenje hude bolečine, ki jo je mogoče obvladati samo z opioidi.
Based on the evaluation of the available data and the scientific discussion within the Committee, the CHMP agreed that the study had convincingly shown that Oxynal and Targin are beneficial in the treatment of symptoms of severe to very severe restless legs syndrome when standard therapy has failed. 
Na podlagi ocene razpoložljivih podatkov in interne znanstvene razprave se je odbor CHMP strinjal, da je študija prepričljivo pokazala, da sta zdravili Oxynal in Targin koristni pri zdravljenju simptomov hudega do zelo hudega sindroma nemirnih nog, kadar je standardna terapija neuspešna.
In particular, there were concerns that the use of Oxynal and Targin could lead to tolerance and misuse and that this was not adequately studied in the clinical trial and the proposed measures to reduce the risk of tolerance and misuse were not considered sufficient. 
Predvsem so bili prisotni pomisleki, da bi lahko uporaba zdravil Oxynal in Targin povzročila toleranco in zlorabo, da tega niso zadostno proučevali v kliničnem preskušanju ter da predlagani ukrepi za zmanjšanje tveganja za toleranco in zlorabo niso zadostni.
In November 2012, the company for Oxynal and Targin applied for an additional use in Germany: treatment of symptoms of severe to very severe restless legs syndrome when treatment with other medicines called dopaminergics has failed. 
Novembra 2012 je družba za zdravili Oxynal in Targin v Nemčiji predložila vlogo za dodatno uporabo: zdravljenje simptomov hudega do zelo hudega sindroma nemirnih nog, kadar zdravljenje z drugimi zdravili, imenovanimi dopaminergiki, ni uspešno.
The Agency's Committee for Medicinal Products for Human Use (CHMP) had been asked to arbitrate on a change to the marketing authorisation for these medicines to include a new use in the treatment of restless legs syndrome. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri Agenciji so pozvali, naj presodi o spremembi dovoljenja za promet s temi zdravili, s katero bi k dovoljenju vključili novo uporabo zdravil, in sicer za zdravljenje sindroma nemirnih nog.
The Committee concluded that the benefits of Oxynal, Targin and associated names outweigh their risks in the new use and the change to the marketing authorisation can be granted in Germany and the following Member States: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Hungary, Ireland, Italy, Latvia, Luxembourg, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the United Kingdom. 
Odbor je zaključil, da so koristi zdravil Oxynal, Targin in povezanih imen pri novi uporabi večje od z njimi povezanih tveganj in da se sprememba dovoljenja za promet z zdravili lahko odobri v Nemčiji in naslednjih državah članicah: v Avstriji, Belgiji, Bolgariji, na Cipru, v Češki republiki, na Danskem, v Estoniji, na Finskem, v Franciji, na Madžarskem, Irskem, v Italiji, Latviji, Luksemburgu, na Nizozemskem, Norveškem, Poljskem, Portugalskem, v Romuniji, na Slovaškem, v Sloveniji, Španiji, na Švedskem in v Združenem kraljestvu.
Questions and answers on Oxynal, Targin and associated names (oxycodone hydrochloride / naloxone hydrochloride) 
Vprašanja in odgovori o zdravilih Oxynal, Targin in povezanih imenih (oksikodonijev klorid/naloksonijev klorid)
The CHMP therefore concluded that the benefits of Oxynal and Targin for restless legs syndrome outweigh their risks and recommended that the change to the marketing authorisation be granted in Germany and the concerned Member States. 
Odbor CHMP je zato zaključil, da so koristi zdravil Oxynal in Targin pri sindromu nemirnih nog večje od z njima povezanih tveganj in priporočil, da se odobri sprememba dovoljenja za promet z zdraviloma v Nemčiji in zadevnih državah članicah.
What are Oxynal and Targin? 
Kaj sta zdravili Oxynal in Targin?
Oxynal and Targin contain two active substances: oxycodone hydrochloride, an opioid painkiller, and naloxone hydrochloride, an opioid antagonist, which is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors found locally in the gut. 
Zdravili Oxynal in Targin vsebujeta dve zdravilni učinkovini: oksikodonijev klorid, opioidni analgetik, in naloksonijev klorid, opioidni antagonist, ki se dodaja za lajšanje zaprtosti, ki jo povzročajo opioidi, tako da zavira delovanje oksikodona na opioidnih receptorjih v črevesju.
The grounds for the referral were concerns from the Netherlands that the data on Oxynal and Targin submitted in the application were not sufficient to demonstrate a positive benefit-risk balance in restless legs syndrome. 
Razlogi za napotitveni postopek so bili pomisleki Nizozemske, da podatki o zdravilih Oxynal in Targin, predloženi v vlogi, niso zadostni za dokazovanje pozitivnega razmerja med tveganji in koristmi pri sindromu nemirnih nog.
Overall summary of the scientific evaluation of Novosis Goserelin 3,6 mg Implantat and associated names (see Annex I) 
Splošni povzetek znanstvenega vrednotenja zdravila Novosis Goserelin 3,6 mg Implantat in z njim povezanih imen (glejte Dodatek I)
• The Committee considered the referral triggered under Article 36 of Directive 2001/83/EC for Novosis Goserelin and associated names as listed in Annex I. 
• Odbor je upošteval napotitveni postopek, sprožen v skladu s členom 36 Direktive 2001/83/ES, za zdravilo Novosis Goserelin in povezana imena, kot določa Priloga I.
The average accumulation factor is about 1.7. 
Povprečni akumulacijski faktor je okrog 1,7.
Based on this data, the tolerability would be expected to be similar between those two groups. 
Na podlagi teh podatkov se pričakuje, da bo toleranca v teh dveh skupinah podobna.
Sessions 4.5, 5.1, and 5.2 have been updated in order to guarantee the safety of the medicine. 
Poglavja 4.5, 5.1 in 5.2 so bila posodobljena z namenom zagotoviti varnost zdravila.
The main areas for harmonisation were as follows. 
Glavna področja usklajevanja so navedena v nadaljevanju.
• sudden loss of consciousness 
• nenadna izguba zavesti
This combination apparently increases the risk for adverse events and is therefore not recommended. 
Kaže, da ta kombinacija povečuje tveganje za neželene učinke, zato ni priporočena.
• swollen face, tongue or throat 
• oteklina obraza, jezika ali grla
2 and 4, rue Lionel Terray 92500 RUEIL-MALMAISON France 
2 and 4, rue Lionel Terray 92500 RUEIL-MALMAISON Francija
• to treat high blood pressure. 
• Za zdravljenje visokega krvnega tlaka.
• the use of Diovan in children and adolescents is not recommended (below the age of 18 years). 
• uporaba zdravila Diovan pri otrocih in mladostnikih (starih manj kot 18 let) ni priporočena,
The issue has been solved 
S tem je bila zadeva rešena.
The CHMP considered that there is little support for the triple combination use so far. 
CHMP je menil, da je imela uporaba trojne kombinacije doslej majhno podporo.
Some symptoms need immediate medical attention: You may experience symptoms of angioedema, such as 
Nekateri simptomi zahtevajo takojšnjo zdravstveno oskrbo: Pojavijo se lahko simptomi angioedema, kot so
This indication was approved in all Member States and the CHMP adopted the following wording: 
Ta indikacija je bila potrjena v vseh državah članicah, zato je CHMP sprejel naslednje besedilo:
Before you drive a vehicle, use tools or operate machines, or carry out other activities that require concentration, make sure you know how Diovan affects you. 
Preden začnete voziti, uporabljati orodje, upravljati stroje ali izvajati druge dejavnosti, ki zahtevajo zbranost, morate zagotovo vedeti, kako zdravilo Diovan deluje na vas.
It is caused when the heart muscle cannot pump blood strongly enough to supply all the blood needed throughout the body. 
Do tega pride takrat, ko srčna črpalka ne more črpati dovolj krvi, da bi s krvjo oskrbela celotno telo.
In addition the VALIANT study demonstrated that mortality was not increased in patients receiving the triple combination. 
Poleg tega je študija VALIANT pokazala, da se umrljivost pri bolnikih, ki so prejemali trojno kombinacijo, ni povečala.
Considering the non inferiority in clinical outcome of valsartan compared to current standard treatment, an ACEI, the CHMP adopted the following harmonised wording for this indication: 
Upoštevajoč neinferiornost kliničnih rezultatov za valsartan v primerjavi s trenutnim standardnim zdravljenjem, ACEI, je CHMP sprejel naslednje usklajeno besedilo za to indikacijo:
The mean treatment duration was two years. 
Zdravljenje je trajalo povprečno dve leti.
OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF DIOVAN AND ASSOCIATED NAMES (SEE ANNEX I) 
SPLOŠNI POVZETEK ZNANSTVENEGA VREDNOTENJA ZDRAVILA DIOVAN IN Z NJIM POVEZANIH IMEN (GLEJTE DODATEK I)
- the Summaries of Products Characteristic, labelling and package leaflet proposed by the Marketing Authorisation Holders have been assessed based on the documentation submitted and the scientific discussion within the Committee, 
- povzetki glavnih značilnosti zdravila, označevanje in navodila za uporabo, ki so jih predlagali imetniki dovoljenja za promet z zdravilom, so bili ovrednoteni na podlagi predložene dokumentacije in znanstvene razprave znotraj Odbora.
• if you are more than 3 months pregnant (it is also better to avoid Diovan in early pregnancy - see pregnancy section). 
• če ste noseči več kot 3 mesece (tudi v zgodnji nosečnosti raje ne jemljite zdravila Diovan) - glejte poglavje nosečnost.
• low blood pressure with symptoms such as dizziness 
• nizek krvni pritisk s simptomi kot je omotičnost
Valsartan also demonstrated beneficial effects on signs and symptoms of HF. 
Valsartan je pokazal tudi koristne učinke na znake in simptome srčnega popuščanja.
The first area of disagreement is about the use of triple combination (Valsartan + ACEI+ BB) in chronic HF. 
Prvo področje nestrinjanja se nanaša na uporabo trojne kombinacije (Valsartan + ACEI + BB) pri kroničnem srčnem popuščanju.
These side effects may occur with certain frequencies, which are defined as follows: very common: affects more than 1 user in 10 common: affects 1 to 10 users in 100 uncommon: affects 1 to 10 users in 1,000 rare: affects 1 to 10 users in 10,000 very rare: affects less than 1 user in 10,000 not known: frequency cannot be estimated from the available data. 
Neželeni učinki se pojavljajo s pogostnostjo, ki je opredeljena spodaj: zelo pogosti: prizadenejo več kot 1 od 10 uporabnikov pogosti: prizadenejo 1 do 10 od 100 uporabnikov občasni: prizadenejo 1 do 10 od 1.000 uporabnikov redki: prizadenejo 1 do 10 od 10.000 uporabnikov zelo redki: prizadenejo manj kot 1 od 10.000 uporabnikov neznana: pogostnosti ni mogoče oceniti iz razpoložljivih podatkov
• other medicines that lower blood pressure, especially water pills (diuretics). 
• druga zdravila za znižanje krvnega tlaka, posebno tablete za odvajanje vode (diuretike),
If symptomatic hypotension or renal dysfunction occur, consideration should be given to a dosage reduction. 
Če pride do simptomatske hipotenzije ali ledvične disfunkcije, je treba razmisliti o zmanjšanju odmerka.
Box 23490 Nicosia Cyprus 
P.O. Box 23490 Nicosia Ciper
However, no safety issue can be predicted because valsartan would not have specific safety issues associated with renal failure in general. 
Vendar pa ni predviden noben zadržek glede varnosti, saj za valsartan ne obstajajo nobeni posebni zadržki glede njegove varnosti v povezavi z odpovedjo ledvic na splošno.
If you forget to take Diovan Do not take a double dose to make up for a forgotten dose. 
Če ste pozabili vzeti zdravilo Diovan Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek.
In some patients whose blood pressure is not adequately controlled, the dose can be increased to 160 mg and to a maximum of 320 mg. 
Bolnikom, pri katerih krvni tlak ni ustrezno urejen, je mogoče odmerek zvečati na 160 mg in na največ 320 mg.
However, the CHMP, requested to summarize all indications in one table, according to the `Guideline of SPC`. 
CHMP pa je zahteval, da se naredi povzetek vseh indikacij v eni tabeli v skladu s „Smernicami za pripravo povzetka glavnih značilnosti zdravila“.
Valsartan does not undergo extensive biotransformation and 70% of the available dose is excreted. 
Pri valsartanu ne pride do obsežne biotransformacije, zato se 70 % razpoložljivega odmerka izloči.